Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BZIAE
ADC Name
Anti-CD33AB-Compound (Ic)
Synonyms
Anti CD33AB Compound (Ic)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
3.07
Structure
Antibody Name
Anti-CD33AB
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
NeoDegrader P1
  Payload Info 
Therapeutic Target
Protein cereblon (CRBN)
  Target Info 
Linker Name
Anti-CD33AB-Compound (Ic) linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 65.26
%
MV4-11 cells
Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 65.26% (Day 46) Positive CD33 expression (CD33+++/++)
Method Description
1 x 107 MV411 human acute monocytic leukemia cells in 50% Matrigel were injected subcutaneously in the flank of the mice (0.1 mL/mouse). The mice were dosed with anti-CD33 antibody-neoDegrader conjugates and vehicle control once tumors reached an average size of 100-150 mm3. The stock solutions of CD33AB-Compound (lc) was diluted with vehicle, which provided, 3 mg/kg in a dosing volume of 10 mL/kg (0.2 mL per 20 g mouse).

   Click to Show/Hide
In Vivo Model MV411 CDX model
In Vitro Model Childhood acute monocytic leukemia MV4-11 cells CVCL_0064
References
Ref 1 Neodegrader conjugates; 2021-10-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.